- Home
- EHAB vs CRMD Comparison
EHAB vs CRMD Comparison
Compare EHAB & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- CRMD
- Stock Information
- Founded
- EHAB 2014
- CRMD 2006
- Country
- EHAB United States
- CRMD United States
- Employees
- EHAB N/A
- CRMD N/A
- Industry
- EHAB Hospital/Nursing Management
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- EHAB Health Care
- CRMD Health Care
- Exchange
- EHAB Nasdaq
- CRMD Nasdaq
- Market Cap
- EHAB 401.6M
- CRMD 464.7M
- IPO Year
- EHAB N/A
- CRMD 2010
- Fundamental
- Price
- EHAB $10.39
- CRMD $12.40
- Analyst Decision
- EHAB Hold
- CRMD Strong Buy
- Analyst Count
- EHAB 3
- CRMD 6
- Target Price
- EHAB $8.50
- CRMD $15.00
- AVG Volume (30 Days)
- EHAB 440.6K
- CRMD 2.2M
- Earning Date
- EHAB 05-07-2025
- CRMD 05-06-2025
- Dividend Yield
- EHAB N/A
- CRMD N/A
- EPS Growth
- EHAB N/A
- CRMD N/A
- EPS
- EHAB N/A
- CRMD 0.28
- Revenue
- EHAB $1,032,300,000.00
- CRMD $82,553,827.00
- Revenue This Year
- EHAB $4.66
- CRMD $239.16
- Revenue Next Year
- EHAB $4.99
- CRMD $53.17
- P/E Ratio
- EHAB N/A
- CRMD $43.73
- Revenue Growth
- EHAB N/A
- CRMD N/A
- 52 Week Low
- EHAB $6.85
- CRMD $3.61
- 52 Week High
- EHAB $10.79
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- EHAB 65.48
- CRMD 65.00
- Support Level
- EHAB $10.30
- CRMD $11.88
- Resistance Level
- EHAB $10.62
- CRMD $12.99
- Average True Range (ATR)
- EHAB 0.25
- CRMD 0.46
- MACD
- EHAB -0.05
- CRMD -0.11
- Stochastic Oscillator
- EHAB 42.96
- CRMD 58.44
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.